Trial reportWorld journal of gastroenterology2007
Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma.
Trial report in World journal of gastroenterology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies.Liver international : official journal of the International Association for the Study of the Liver · 2009Pooled it
- Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Interleukin-18 armours antitumour immune effectors.Nature reviews. Immunology · 2026Review
- Review
- Cytokine biomarkers for independent prediction of hepatocellular carcinoma prognosis.Discover oncology · 2025Review
- Pre-diagnostic plasma inflammatory proteins and risk of hepatocellular carcinoma in three population-based cohort studies from the United States and the United Kingdom.International journal of cancer · 2024Article
- ACSL6-activated IL-18R1-NF-κB promotes IL-18-mediated tumor immune evasion and tumor progression.Science advances · 2024Article
- Article
- Comprehensive multi-omics analysis of pyroptosis for optimizing neoadjuvant immunotherapy in patients with gastric cancer.Theranostics · 2024Article
- Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma.World journal of gastrointestinal oncology · 2023Article
- Interleukin-10 in cancer immunotherapy: from bench to bedside.Trends in cancer · 2023Review
- Proteomics of adjacent-to-tumor samples uncovers clinically relevant biological events in hepatocellular carcinoma.National science review · 2023Article
- The Role of IL-18 in P2RX7-Mediated Antitumor Immunity.International journal of molecular sciences · 2023Review
- Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma.Oncology · 2023Article
- Pyroptosis Provides New Strategies for the Treatment of Cancer.Journal of Cancer · 2023Review
- Different races have different immune microenvironments: comparison of White and Asian patients with liver cancer.American journal of cancer research · 2023Article
- Interleukin-18 in metabolism: From mice physiology to human diseases.Frontiers in endocrinology · 2022Review
- Chemotherapeutic Drug-Regulated Cytokines Might Influence Therapeutic Efficacy in HCC.International journal of molecular sciences · 2021Review
- Interleukin-6 Induced Proliferation Is Attenuated by Transforming Growth Factor-β-Induced Signaling in Human Hepatocellular Carcinoma Cells.Frontiers in oncology · 2021Article
- Effect of HBx on inflammation and mitochondrial oxidative stress in mouse hepatocytes.Oncology letters · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo determine whether serum interleukin-18 (IL-18) levels correlated with clinicopathologic features and prognosis in patients with hepatocellular carcinoma (HCC).
methodsSerum IL-18, IL-6 and IL-12 levels were measured by enzyme-linked immunosorbent assay (ELISA) from 70 patients with HCC and 10 healthy controls.
resultsSerum IL-18, IL-6 and IL-12 levels of patients with HCC were significantly higher that those of the controls. The levels of IL-18 correlated significantly with the presence of venous invasion and advanced tumor stages classified by Okuda's criteria. Patients with high serum IL-18 levels (>= 10(5) pg/mL) had a poorer survival than those with low serum IL-18 levels (< 10(5) pg/mL) (4 and 11 mo, respectively, P = 0.015). Multivariate analyses showed that serum IL-18 level, but not IL-6 and IL-12 levels, was a significant and independent prognostic factor of survival.
conclusionThese findings demonstrate that serum IL-8 may a useful biological marker of tumor invasiveness and an independent prognostic factor of survival for patients with HCC. Thus, the detailed mechanisms of IL-18 involving in tumor progression should be further investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.